Holen Sie sich die Stockscreener-App
41.09
2.21%
0.89
Handel nachbörslich:
41.09
Schlusskurs vom Vortag:
$40.20
Offen:
$40.83
24-Stunden-Volumen:
1.27M
Relative Volume:
0.70
Marktkapitalisierung:
$7.34B
Einnahmen:
$29.52M
Nettoeinkommen (Verlust:
$-567.06M
KGV:
-11.23
EPS:
-3.66
Netto-Cashflow:
$-551.11M
1W Leistung:
+4.29%
1M Leistung:
+9.75%
6M Leistung:
-14.52%
1J Leistung:
+2.34%
1-Tages-Spanne:
$40.15
$41.94
1-Wochen-Bereich:
$39.51
$41.94
52-Wochen-Spanne:
$29.17
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
Firmenname
Revolution Medicines Inc
Sektor
Branche
Telefon
415-766-3638
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Vergleichen Sie RVMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
41.09 | 7.34B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-16 | Bestätigt | Needham | Buy |
| 2024-07-12 | Eingeleitet | Barclays | Overweight |
| 2024-07-08 | Eingeleitet | Jefferies | Buy |
| 2024-04-12 | Bestätigt | Needham | Buy |
| 2024-04-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-04 | Eingeleitet | Wedbush | Outperform |
| 2023-11-16 | Eingeleitet | Raymond James | Outperform |
| 2023-02-28 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-05-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-03-01 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-08-12 | Herabstufung | Goldman | Buy → Neutral |
| 2021-05-18 | Eingeleitet | Goldman | Buy |
| 2020-05-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-09 | Eingeleitet | Cowen | Outperform |
| 2020-03-09 | Eingeleitet | Guggenheim | Buy |
| 2020-03-09 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
(RVMD) Investment Analysis - news.stocktradersdaily.com
rEvolution Appoints Brian Gabriel as Vice President of Marketing Communications - GlobeNewswire Inc.
Revolution Medicines’ SWOT analysis: stock shows promise amid clinical progress - Investing.com Nigeria
(RVMD) On The My Stocks Page - news.stocktradersdaily.com
First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trial - Yahoo Finance
Revolution Medicines begins phase 3 trial for lung cancer drug By Investing.com - Investing.com Canada
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer - BioSpace
Revolution Medicines (RVMD) Receives Adjusted Price Target from - GuruFocus
When (RVMD) Moves Investors should Listen - news.stocktradersdaily.com
Revolution Medicines (RVMD) Initiates RASolve 301 Phase 3 Trial - GuruFocus
Revolution Medicines begins phase 3 trial for lung cancer drug - Investing.com
Revolution Medicines Announces First Patient Dosed in Phase - GlobeNewswire
Revolution Medicines (RVMD) Price Target Reduced by H.C. Wainwri - GuruFocus
Revolution Medicines price target lowered to $72 from $73 at H.C. Wainwright - TipRanks
Revolution medicines outlines 2025 focus on RAS(ON) inhibitors in key cancer trials - MSN
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - Yahoo Finance
We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth - Yahoo Finance
Revolution’s KRAS drugs appear competitive in several lung cancer settings - Endpoints News
Revolution Medicines’ Earnings Call: Optimism Amid Rising Costs - TipRanks
RVMD: Guggenheim Maintains Buy Rating, Lowers Price Target to $8 - GuruFocus
The Lustgarten Foundation Honors Revolution Medicines for Transformative Research in Pancreatic Cancer - PRWeb
Oppenheimer Raises Price Target for RVMD, Maintains Outperform R - GuruFocus
RVMD Price Target Lowered but Buy Rating Maintained by Guggenheim | RVMD Stock News - GuruFocus
Revolution Medicines (RVMD) Target Price Raised Amid Positive Ou - GuruFocus
Revolution Medicines (RVMD) Target Price Raised Amid Positive Outlook | RVMD Stock News - GuruFocus
Needham Reiterates Buy Rating for Revolution Medicines (RVMD) | RVMD Stock News - GuruFocus
Revolution Medicines Inc (RVMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Revolution Medicines Inc (RVMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - GuruFocus
Revolution Medicines Reports Q1 2025 Financial Results - TipRanks
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insig - GuruFocus
Revolution Medicines Inc Reports Q1 2025 EPS of -$1.13 and Reven - GuruFocus
Revolution Medicines (RVMD) Advances Key Clinical Trials and Str - GuruFocus
Earnings call transcript: Revolution Medicines sees stock surge after Q1 2025 update - Investing.com
Revolution Medicines Q1 2025 Earnings Call Transcript - MarketBeat
Revolution Medicines Q1 Net Loss Widens - marketscreener.com
Revolution Medicines (RVMD) Advances Key Clinical Trials and Strengthens Team | RVMD Stock News - GuruFocus
Revolution Medicines Inc Reports Q1 2025 EPS of -$1.13 and Revenue of $0.00 Million, Missing Estimates - GuruFocus
Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress - The Manila Times
Revolution Medicines patents new GTPase KRAS mutant inhibitors - BioWorld MedTech
(RVMD) Investment Report - news.stocktradersdaily.com
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Regeneron (REGN) - The Globe and Mail
Revolution Medicines Inc [RVMD] Records 50-Day SMA of $37.82 - knoxdaily.com
Revolution Medicines Sets Date for Q1 2025 Financial Results: Key Updates Expected from RAS Cancer Pipeline - Stock Titan
Revolution Medicines, Inc. to Report Q1 2025 Financial Results on May 7, 2025 - Nasdaq
Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025 - GlobeNewswire
Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday? - AOL.com
Revolution Medicines’ (RVMD) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Revolution Medicines (RVMD) Reports Promising Data for Zoldonras - GuruFocus
A Guide To The Risks Of Investing In Revolution Medicines Inc (RVMD) - knoxdaily.com
Revolution Medicines Shares Rise on 'Encouraging' Phase 1 Lung Cancer Trial Data - marketscreener.com
Revolution’s Next KRAS Drug Shows Promise In NSCLC - insights.citeline.com
Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):